There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allena Pharmaceuticals Inc (ALNA) and Spectrum Pharmaceuticals (SPPI) with bullish sentiments.
Allena Pharmaceuticals Inc (ALNA)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Allena Pharmaceuticals Inc today and set a price target of $38. The company’s shares opened today at $5.46, close to its 52-week low of $4.80.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -12.9% and a 30.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Global Blood Therapeutics, and Liquidia Technologies Inc.
Currently, the analyst consensus on Allena Pharmaceuticals Inc is a Strong Buy with an average price target of $30, which is a 449.5% upside from current levels. In a report issued on December 21, B.Riley FBR also initiated coverage with a Buy rating on the stock with a $22 price target.
.
See today’s analyst top recommended stocks >>
Spectrum Pharmaceuticals (SPPI)
H.C. Wainwright analyst Edward White maintained a Buy rating on Spectrum Pharmaceuticals today and set a price target of $40. The company’s shares opened today at $8.57, close to its 52-week low of $6.22.
White said:
“Our $40 price target is derived from an NPV of Spectrum’s proprietary pipeline, a sum-of-the-parts analysis based on the P/E value of its current commercial business, plus cash. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 3x. We value the pipeline at $12.19 per share (x3= $36.57), the current commercial business at $1.48 per share and YE18 estimated fully diluted net cash at $1.49 per share.”
According to TipRanks.com, White is a 5-star analyst with an average return of 11.5% and a 44.3% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Synthetic Biologics Inc, and Karyopharm Therapeutics.
Currently, the analyst consensus on Spectrum Pharmaceuticals is a Moderate Buy with an average price target of $30.50, representing a 255.9% upside. In a report issued on December 20, B.Riley FBR also maintained a Buy rating on the stock with a $21 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
